Basking Ridge, NJ-based Ipsen Biopharmaceuticals announced Aug. 1 that the Food and Drug Administration (FDA) had given the nod to its abobotulinumtoxinA injection for treatment of pediatric lower limb spasticity in children aged 2 years and older. It’s the first FDA-approved botulinum toxin for treatment of pediatric lower limb spasticity, according to a company release
Read the article:
FDA approves Dysport for kids with CP